Performance evaluation of Biofire Film Array Respiratory Panel 2.1 for SARS-CoV-2 detection in a pediatric hospital setting

被引:2
作者
Mesquita Ramirez, Mirta [1 ]
Noemi Zarate, Miria [1 ]
Adelaida Rodriguez, Leonidas [1 ]
Hugo Aquino, Victor [2 ]
机构
[1] Gen Pediat Hosp Children Acosta Nu, San Lorenzo, Central, Paraguay
[2] Natl Univ Asuncion, Res Inst Hlth Sci, Dept Immunol, San Lorenzo, Central, Paraguay
来源
PLOS ONE | 2023年 / 18卷 / 10期
关键词
COVID-19; CHILDREN; IMPACT;
D O I
10.1371/journal.pone.0292314
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The highly contagious nature of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), requires rapid diagnostic tests to prevent the virus from spreading within hospitals and communities. Reverse transcription followed by the polymerase chain reaction (RT-PCR) test is the gold standard for detecting SARS-CoV-2 infections but is time-consuming, labor-intensive, and restricted to centralized laboratories. There is a growing need to develop and implement point-of-care and rapid tests for SARS-CoV-2 detection to address these limitations. We aimed to evaluate the performance of BioFire Film Array Respiratory Panel 2.1 (BioFire FA-RP2.1) for SARS-CoV-2 detection in a pediatric hospital setting. The BioFire FA-RP2.1 test provides rapid results and can identify several viral and bacterial infections in a single test. This prospective, cross-sectional, diagnostic accuracy study enrolled participants ranging from 0 to 18 years of age, seeking medical consultation for any reason, who had been in contact with individuals confirmed to have COVID-19 or managed at the hospital for medical or surgical reasons. We employed a systematic sampling technique to ensure a representative sample. The study included 339 participants with a median age of 5 years. The BioFire FA-RP2.1 test detected SARS-CoV-2 in 18.6% of cases, while the reference RT-PCR test in 14% of cases. The BioFire FA-RP2.1 sensitivity and specificity for SARS CoV-2 detection were 98% and 94%, respectively. The positive probability coefficient (LR+) was 18. The agreement between the two tests was 0.80. In addition, the BioFire FA-RP2.1 test detected coinfection with two viruses in 7,6% of cases. The BioFire FA-RP2.1 is a reliable solution to meet pediatric healthcare needs and improve prognosis in the post-pandemic era thanks to its friendly interface and rapid testing process.
引用
收藏
页数:13
相关论文
共 37 条
  • [1] Attwood Lucy O, 2020, J Clin Virol, V128, P104448, DOI 10.1016/j.jcv.2020.104448
  • [2] Influenza and respiratory syncytial virus during the COVID-19 pandemic: Time for a new paradigm?
    Binns, Emma
    Koenraads, Marianne
    Hristeva, Lidia
    Flamant, Alix
    Baier-Grabner, Sebastian
    Loi, Mervin
    Lempainen, Johanna
    Osterheld, Elise
    Ramly, Bazlin
    Chakakala-Chaziya, Jessica
    Enaganthi, Niveditha
    Simo Nebot, Silvia
    Buonsenso, Danilo
    [J]. PEDIATRIC PULMONOLOGY, 2022, 57 (01) : 38 - 42
  • [3] Bordi L, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104416
  • [4] Point-of-Care and Rapid Tests for the Etiological Diagnosis of Respiratory Tract Infections in Children: A Systematic Review and Meta-Analysis
    Brigadoi, Giulia
    Gastaldi, Andrea
    Moi, Marco
    Barbieri, Elisa
    Rossin, Sara
    Biffi, Annalisa
    Cantarutti, Anna
    Giaquinto, Carlo
    Da Dalt, Liviana
    Dona, Daniele
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (09):
  • [5] The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review
    Chuang, Yu-Chuan
    Lin, Kuan-Pei
    Wang, Li-An
    Yeh, Ting-Kuang
    Liu, Po-Yu
    [J]. INFECTION AND DRUG RESISTANCE, 2023, 16 : 661 - 675
  • [6] Clinical evaluation of the BioFire® Respiratory Panel 2.1 and detection of SARS-CoV-2
    Creager, Hannah M.
    Cabrera, Barbara
    Schnaubelt, Andy
    Cox, Jesse L.
    Cushman-Vokoun, Allison M.
    Shakir, Salika M.
    Tardif, Keith D.
    Huang, Meei-Li
    Jerome, Keith R.
    Greninger, Alexander L.
    Drobysheva, Daria
    Spaulding, Usha
    Rogatcheva, Margarita
    Bourzac, Kevin M.
    Hinrichs, S. H.
    Broadhurst, M. J.
    Fey, P. D.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2020, 129
  • [7] Rapid differential diagnosis of SARS-CoV-2, influenza A/B and respiratory syncytial viruses: Validation of a novel RT-PCR assay
    Domnich, Alexander
    Bruzzone, Bianca
    Trombetta, Carlo-Simone
    De Pace, Vanessa
    Ricucci, Valentina
    Varesano, Serena
    Garzillo, Giada
    Ogliastro, Matilde
    Orsi, Andrea
    Icardi, Giancarlo
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2023, 161
  • [8] Epidemiology of COVID-19 Among Children in China
    Dong, Yuanyuan
    Mo, Xi
    Hu, Yabin
    Qi, Xin
    Jiang, Fan
    Jiang, Zhongyi
    Tong, Shilu
    [J]. PEDIATRICS, 2020, 145 (06)
  • [9] Comparison of eleven in vitro diagnostic assays for the detection of SARS-CoV-2 RNA
    Dundon, G. William
    Settypalli, B. K. Tirumala
    Spiegel, Katharina
    Steinrigl, Adi
    Revilla-Fernandez, Sandra
    Schmoll, Friedrich
    Naletoski, Ivancho
    Lamien, E. Charles
    Cattoli, Giovanni
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2021, 295
  • [10] Evaluation of the BioFire® COVID-19 test and Respiratory Panel 2.1 for rapid identification of SARS-CoV-2 in nasopharyngeal swab samples
    Eckbo, Eric J.
    Locher, Kerstin
    Caza, Melissa
    Li, Lisa
    Lavergne, Valery
    Charles, Marthe
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2021, 99 (03)